Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40000719
Localisation
United Kingdom
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
SME
Dernière mise à jour
19/09/2024
Statut
Classification
1.5°C
Année cible
2030
This target was approved using a streamlined target validation route exclusive to small and medium-sized enterprises (SMEs). https://docs.sbtiservices.com/resources/FAQsforSMEs.pdf OXON Epidemiology commits to maintain zero scope 1 emissions through 2030. OXON Epidemiology also commits to reduce absolute scope 2 GHG emissions 42% by 2030 from a 2023 base year, and to measure and reduce its scope 3 emissions.
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
LEI
8945000E0IMN21HX1R85
Source : Science Based Targets initiative | Données publiques